Molina Healthcare (MOH) Q1 2026 earnings review
Earnings Reset Begins: Shrinking the Base to Save the Margin
Molina is executing a painful but necessary strategic retreat. After a devastating second half of 2025, Q1 2026 shows sequential stabilization, but the year-over-year comparables remain brutal. Adjusted EPS collapsed 61% to $2.35 as the company deliberately shed over 350,000 Marketplace members to escape toxic risk pools. A $93M impairment charge signals the end of their traditional Medicare Advantage-Part D (MAPD) product. Reaffirming the severely lowered $5.00 full-year EPS guidance suggests management believes the worst of the medical cost spikes are contained, but the path back to historical profitability is steep and heavily reliant on favorable state Medicaid rate negotiations.
🐂 Bull Case
The consolidated Medical Care Ratio (MCR) improved sequentially from 94.6% in 25Q4 to 91.1% in 26Q1. Management noted medical cost trends were 'modestly favorable' to their expectations.
Molina is actively cutting out unprofitable revenue. Exiting MAPD and shrinking the volatile Marketplace footprint proves management is prioritizing margin recovery over top-line vanity metrics.
🐻 Bear Case
Adjusted EPS is down 61% YoY. The reaffirmed FY26 guidance of '$5.00+' is a fraction of the $24.50 guidance the company initially projected for FY25 a year ago.
The core Medicaid segment MCR is still elevated at 92.0% (up from 90.3% a year ago), indicating that state reimbursement rates are still lagging behind actual healthcare utilization.
⚖️ Verdict: ⚪
Neutral. The worst appears to be over sequentially, but the year-over-year baseline has been decimated. The company is in a transition year, making tough choices to build a healthier foundation for 2027.
Key Themes
Strategic Marketplace Retreat is Working
Marketplace segment revenue dropped 28% YoY to $724M, driven by a purposeful reduction in membership (down from 662k to 305k). This aggressive pricing strategy successfully Reversing the disastrous 99.0% MCR seen in 25Q4, bringing it down to 84.0% in Q1 (and an even healthier 79.5% when normalizing for prior-year risk adjustments).
Exiting MAPD to Focus on Dual-Eligibles
Molina recorded a $93M impairment charge related to its decision to exit the traditional Medicare Advantage-Part D (MAPD) product by 2027. This represents a major product portfolio shift, removing roughly $1B in annual underperforming premium revenue to focus exclusively on the higher-margin, specialized Dual-Eligible Medicare population.
Broad Membership Contraction
Total membership is Decelerating sharply, down nearly 720,000 members year-over-year to 5.03M. While the Marketplace drop was intentional, the Medicaid segment also lost over 300,000 members (down to 4.49M) due to general market contraction and the expiration of the Virginia contract.
Medicaid Rate/Trend Imbalance
Despite management claiming medical cost trends were 'modestly favorable,' the data shows the core Medicaid MCR degraded YoY from 90.3% to 92.0%. This contradicts the narrative of immediate relief and confirms the macro environment remains hostile, with state rate updates continuing to trail actual medical inflation.
Other KPIs
Accelerating significantly from $190M in 25Q1. Management attributed this massive inflow to the timing of government receivables and payables rather than a surge in underlying earnings power. This bolsters the balance sheet during a volatile earnings period.
Decelerating profitability slightly compared to 6.9% in 25Q1. Adjusted G&A stood at 6.9% vs 6.3% a year ago. The loss of fixed-cost leverage from shedding 700k members is putting upward pressure on administrative expense ratios.
Guidance
Stable. The company reaffirmed its full-year top-line target, which represents a ~2% contraction from FY25, reflecting the deliberate shrinkage of the Marketplace and MAPD books.
Stable. Management reaffirmed this target. With $2.35 already achieved in Q1, the guidance implies a highly conservative run-rate (averaging ~$0.88 per quarter) for the rest of the year, likely leaving room for potential outperformance or buffering against further mid-year Medicaid cost spikes.
Stable. Heavily burdened by the $93M impairment charge taken in Q1 for the MAPD exit, but reaffirmed for the full year.
Key Questions
Pacing of FY26 Earnings
You generated $2.35 of Adjusted EPS in Q1 against a full-year guide of 'at least $5.00'. Are you assuming medical cost trends will accelerate again in the second half, or is this guide purely building in a heavy layer of conservatism?
G&A De-leveraging
With the strategic exit of the MAPD product and the halving of the Marketplace book, how are you right-sizing your fixed administrative costs to prevent sustained upward pressure on the G&A ratio?
Medicaid 'Modestly Favorable' Context
You noted medical cost trends were modestly favorable to expectations, yet Medicaid MCR is up 170 bps year-over-year. Which specific sub-segments (e.g., behavioral, pharmacy, LTSS) drove the favorable variance versus internal models?